The Therapeutic ImmunoModulator Expeditor at the Icahn School of Medicine at Mount Sinai is a scientific, unified interdepartmental* initiative developed under the leadership of Miriam Merad, MD, PhD, Dean of Translational Research and Therapeutic Innovation, to make Mount Sinai the partner of choice for industry collaborators developing innovative immunomodulatory drugs. This initiative aims to bring groundbreaking therapies quickly to patients by overcoming unique structural barriers to opening translational clinical trials efficiently. It also seeks to further translational collaborations between industry partners, Mount Sinai laboratories, and the newly launched Academic Research Organization, OCCAM Immune.

OCCAM Immune offers an immunological monitoring platform to assess the efficacy of novel, innovative compounds through drug targets, immunological changes, biomarkers, and more.

*This unified effort will work with the Tisch Cancer Institute (TCI) and the Department of Medicine, as well as, additional Departments.